We estimated the cancer cell fraction of SLC7A8 p.T184P for each patient during the treatments, which was higher in PD patients (PD_P1_C3: 0.26, PD_P2_C3: 0.23) than in the PR patient (PR_P1_C2: 0.09; Figure 5C). Here, SLC7A8 is linked to cancer.